ClinicalTrials.gg
RecruitingNCT07073040PROSPECTUpdated Jan 30, 2026

Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention in Patients With Diabetic Foot Ulcers and Lower Extremity Arterial Occlusion

An interventional study of Cold atmospheric plasma (CAP) and Sham Procedure in Diabetic Foot Ulcers (DFU) and Lower Extremity Arterial Occlusion, sponsored by Shenyang Medical College. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Shenyang Medical College · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Diabetic Foot with a site in China — 21 open to participants now, 24 under way, 1 of them phase 3. Diabetic Foot · China.

Planned enrollment
17th of 41
86 · median 70
Started
2025
with 4 others
No phase
16 of 52
9 open now
Primary completion
2026-04
later than 10 of 23 live
Registered
44th of 52
by date
Lead sponsor
2 of 52
Shenyang Medical College

Among the 52 studies in Diabetic Foot with a site in China, this one is the 17th largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 with no phase, reaches primary completion later than 10 of the 23 other live ones, and was the 44th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

21 of the 52 studies in Diabetic Foot with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Diabetic Foot with a site in China, or all of them as a file.
02

Study summary

Critical limb ischemia is the end-stage manifestation of peripheral arterial disease (PAD), frequently presenting as ischemic rest pain, ulceration, or gangrene. Diabetes mellitus is a major risk factor for lower extremity arterial occlusion, with infrapopliteal arteries most commonly affected. Patients with diabetic foot ulcers (DFUs) have a high prevalence of neurovascular complications, poor healing, and elevated amputation and mortality rates. Large-scale cohort studies indicate that five-year survival after amputation in this population is only about 50%, underscoring the need for more effective therapies.

Endovascular revascularization has become the first-line treatment for diabetic lower limb ischemia. However, despite successful revascularization, persistent microvascular dysfunction and difficult-to-heal ulcers remain common due to chronic inflammation, impaired angiogenesis, and tissue repair deficits. Current advanced wound dressings provide limited benefit and are often costly.

Cold atmospheric plasma (CAP) has emerged as a promising adjunctive therapy, with demonstrated antimicrobial activity-including efficacy against multidrug-resistant organisms-and the ability to promote microcirculation and wound healing. CAP generates reactive oxygen and nitrogen species that disrupt bacterial membranes and may also stimulate tissue regeneration. Preclinical and clinical studies suggest that CAP can accelerate healing in chronic wounds and is well tolerated by patients.

Given these advantages, the present study aims to assess the efficacy and safety of CAP combined with endovascular intervention in patients with diabetic foot ulcers and lower extremity arterial occlusion, to inform future clinical application of this novel technology.

Read the detailed description

End-stage peripheral arterial disease (PAD) is characterized by critical limb ischemia, which manifests clinically as insufficient arterial perfusion leading to ischemic rest pain, ulceration, and gangrene. A substantial proportion of these cases occur in patients with diabetes complicated by lower extremity arterial occlusion. Ischemia in diabetic patients predominantly affects infrapopliteal arteries, often presenting bilaterally and symmetrically, with diffuse lesions that commonly involve the entire vessel wall. These patients are more prone to both intimal atherosclerosis and medial arterial calcification.

A large multicenter cohort study in China that enrolled 669 patients with diabetic foot ulcers from 15 tertiary hospitals reported that more than 98% had underlying neurovascular pathology. The overall amputation rate was 19.03%, with major and minor amputation rates of 2.14% and 16.88%, respectively. Notably, the five-year survival rate after amputation was approximately 50%, which is lower than that observed for many malignancies. According to a large European cohort study, about half of diabetic foot ulcers are attributable to neuropathic or ischemic etiologies. Both macrovascular and microvascular dysfunctions jointly impair tissue perfusion and exacerbate diabetic foot pathology. From a clinical perspective, successful arterial revascularization alone is not sufficient; maintenance and optimization of distal microcirculatory perfusion following revascularization are also essential for effective ulcer healing.

With advances in endovascular techniques, infrapopliteal angioplasty has become the first-line treatment for diabetic lower limb ischemia, with proven efficacy. However, even after successful revascularization, some patients continue to suffer from inadequate distal perfusion due to microembolization or from persistent, hard-to-heal ulcers driven by the underlying pathophysiology of diabetic wounds. Several studies have demonstrated that diabetic patients experience metabolic dysregulation, local wound hyperglycemia, and accumulation of advanced glycation end-products (AGEs); combined with immune dysfunction and chronic inflammation, these factors maintain wounds in a persistent inflammatory state. Chronic inflammation suppresses vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG-1) expression, impairs endothelial cell function, and leads to angiogenesis disorders and delayed tissue repair. Reduced VEGF and ANG-1 expression has been confirmed in skin specimens from diabetic patients. In addition, peripheral neuropathy further inhibits neovascularization.

Despite widespread clinical use of advanced wound dressings-such as hydrogels, natural or synthetic polymer-based products, and other dressings designed specifically for diabetic ulcers-treatment efficacy remains limited, and costs can be substantial. For patients with diabetic foot ulcers complicated by large-vessel occlusion, ongoing assessment and support of distal microvascular perfusion remain a major unmet clinical need, even after successful revascularization.

Cold atmospheric plasma (CAP) has been widely adopted in medical applications and has demonstrated robust antimicrobial activity as well as the capacity to enhance tissue microcirculation and promote wound healing, with excellent patient tolerance. Multiple preclinical and clinical studies have confirmed the bactericidal efficacy of CAP, including activity against multidrug-resistant organisms. For example, Brun et al. reported that CAP effectively eradicates Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) in vitro, achieving results comparable to antibiotics but with higher efficiency. Lis et al. found that CAP could also inactivate MRSA, Klebsiella pneumoniae, and Acinetobacter baumannii. Korean researchers Kim et al. demonstrated that CAP effectively disrupts biofilms formed by P. aeruginosa and other pathogens in canine skin and ear infections. In a prospective clinical study, Stratmann et al. showed that CAP treatment accelerates wound healing in diabetic foot ulcers. Boekema et al. [6] reported a significant reduction in bacterial load and no serious adverse events in patients with P. aeruginosa infections treated with CAP, confirming its safety profile.

The antimicrobial mechanism of CAP is primarily attributed to the generation of reactive oxygen and nitrogen species (RONS), which induce local free radical formation and disrupt microbial membranes, leading to apoptosis without fostering antimicrobial resistance. This highlights CAP as a valuable adjunct to conventional antibiotic therapy, especially for wounds infected with multidrug-resistant bacteria.

Importantly, CAP's benefits extend beyond antimicrobial effects. Numerous studies indicate that CAP promotes wound healing not only by eliminating pathogens but also by directly activating tissue regeneration. At the cellular level, CAP has been shown to modulate fibroblasts, vascular endothelial cells, and keratinocytes. Stratmann et al. observed that CAP enhanced tissue regeneration in diabetic foot ulcers without a corresponding decrease in colony-forming units, suggesting a regeneration mechanism independent of bactericidal action. In the study by Brehmer et al., CAP (PlasmaDerm device) significantly improved healing rates in lower extremity venous ulcers compared with standard care. These findings imply that CAP can accelerate tissue regeneration and shorten healing time, regardless of its antimicrobial effects.

Delayed wound healing is often accompanied by local microcirculatory disorders, resulting in decreased collagen production and impaired proliferation and migration of keratinocytes and fibroblasts. Several clinical trials have demonstrated that CAP exposure at therapeutic doses increases local skin blood flow and tissue oxygen saturation without raising skin temperature. The underlying mechanism may involve nitric oxide (NO) permeation, modulation of cysteine disulfide bonds and acidic lipid groups, reduced local pH, and improved microcirculation. In animal and cellular experiments, Arndt et al. demonstrated that CAP induces oxidative stress pathways in a paracrine and autocrine manner, stimulating keratinocytes, fibroblasts, and endothelial cells to produce vascular growth factors (EGF, FGF-2, IL-8, uPA, angiopoietin, VEGF), thereby promoting angiogenesis.

Based on these findings, this study aims to evaluate the efficacy and safety of CAP combined with endovascular intervention in patients with diabetic foot ulcers complicated by lower extremity arterial occlusion, providing essential evidence to support future large-scale clinical application of CAP.

03

Conditions studied

  • Diabetic Foot Ulcers (DFU)
  • Lower Extremity Arterial Occlusion

Browse trials for

Keywords

  • cold atmospheric plasma
  • diabetic foot ulcers
  • lower extremity arterial occlusion
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-80 years, with a diagnosis of type 1 or type 2 diabetes and diabetic foot ulcer; (HbA1c) ≤ 10%.
  • Presence of at least one chronic foot ulcer persisting for at least three weeks, with no signs of healing after standard-of-care treatment based on current clinical guidelines. The ulcer must be classified as Wagner-Armstrong grade 1D or 2D (Wagner: superficial ulcer [grade 1] or ulcer extending to tendon [grade 2]; Armstrong: presence of both ischaemia and infection [stage D]).
  • Documented infrapopliteal arterial stenosis or occlusion by vascular ultrasound and/or CT angiography (CTA), meeting indications for revascularization. All enrolled patients must have received successful infrapopliteal balloon angioplasty, with intraoperative angiography confirming target artery patency.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Concurrent treatment of the wound with local vacuum therapy or maggot therapy.
  • Undergoing dialysis.
  • Use of local active antibiotics.
  • Treatment with -rich fibrin.
  • Women of without effective , or women who are actively breastfeeding.
  • Presence of other severe organ dysfunction, with an expected survival of less than six months.
  • Participation in another clinical trial within the past three months or currently enrolled in another clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Active comparator
    CAP therapy

    Device: Cold atmospheric plasma (CAP) · Other: Successful infrapopliteal angioplasty

  • Placebo comparator
    the placebo group

    Device: Sham Procedure · Other: Successful infrapopliteal angioplasty

Interventions

  • DeviceCold atmospheric plasma (CAP)

    CAP therapy will be administered once daily for the first five days and then every other day thereafter, for a total of 13 sessions. Each session will last approximately 25 minutes, as recommended by the manufacturer. During treatment, the affected limb will be enclosed in a sterile treatment bag, sealed with medical adhesive tape. The CAP device will operate in two sequential modes: a "disinfection mode" delivering ozone-rich (O₃) plasma-activated gas for 20 minutes, followed by a "healing mode" delivering nitric oxide (NO)-rich plasma-activated gas for 5 minutes. All procedures will be performed in accordance with the manufacturer's instructions and the device's standard operating protocol.

  • DeviceSham Procedure

    Participants in the placebo group will undergo a sham procedure, in which the electric field required for plasma generation will be disabled, so that no plasma will be produced. Only the operating sounds of the device will be simulated, ensuring blinding for both participants and clinical staff.

  • OtherSuccessful infrapopliteal angioplasty

    All patients will undergo successful infrapopliteal angioplasty, with less than 30% residual stenosis confirmed by digital subtraction angiography.

06

What researchers measure

Primary outcomes

  1. Change in ulcer area between groups

    The ulcer area (cm²) will be measured daily during the first five days, and every other day for the subsequent eight visits (13 follow-up assessments in total)

    Time frame: From Baseline (Day 0) to Day 21 post-randomization

Secondary outcomes

  1. Time to 10% reduction in ulcer area

    The time from randomization to the first occurrence of a 10% reduction in ulcer area

    Time frame: From Baseline (Day 0) to Day 21 post-randomization

  2. Time to 20% reduction in ulcer area

    The time from randomization to the first occurrence of a 20% reduction in ulcer area.

    Time frame: From Baseline (Day 0) to Day 21 post-randomization

  3. Time to onset of clinical signs of infection

    The time from randomization to the first documented clinical sign of wound infection.

    Time frame: From Baseline (Day 0) to Day 21 post-randomization

  4. Change in pain score

    Change in pain score, assessed by the Visual Analogue Scale (VAS; 0 = no pain, 10 = worst imaginable pain; higher scores indicate greater pain severity)

    Time frame: From Baseline (Day 0) to Day 21 post-randomization

  5. Change in quality of life (EQ-5D questionnaire)

    Time frame: Baseline (Day 0) and Day 21 post-randomization

  6. Change in quality of life (SF-12 questionnaire)

    Time frame: Baseline (Day 0) and Day 21 post-randomization

  7. Incidence of local skin irritation

    Time frame: From Baseline (Day 0) to Day 21 post-randomization

  8. Incidence of local bleeding

    Time frame: From Baseline (Day 0) to Day 21 post-randomization

  9. Incidence of local burning sensation

    Time frame: From Baseline (Day 0) to Day 21 post-randomization

Other outcomes

  1. Change in pain score

    Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization

  2. Change in quality of life (EQ-5D questionnaire)

    Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization

  3. Change in quality of life (SF-12 questionnaire)

    Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization

  4. Incidence of keloid formation

    Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization

  5. Incidence of amputation

    Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization

  6. All-cause mortality

    Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization

07

Study locations

1 of 1 sites recruiting
  • Ansteel General Hospital
    Anshan, Liaoning, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2026, 8 months after the start.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 8 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2025
First posted
Jul 18, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Apr 10, 2026
CompletionEst.
May 6, 2026
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07073040
Lead sponsor
Shenyang Medical College
Collaborators
Ansteel General Hospital, Tsinghua University
Responsible party
Lin Tao (Associate Professor, Shenyang Medical College) — Principal investigator
First posted
Jul 18, 2025
Start date
Jul 22, 2025
Primary completion
Apr 10, 2026 (estimated)
Completion
May 6, 2026 (estimated)
Last update
Jan 30, 2026

Study contacts

Yun-En Liu, MD
Contact
lye9901@163.com
86-24-62215130
Yun-En Liu, MD
study chair · Shenyang Medical College
Lin Tao, MM
principal investigator · Shenyang Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion